D11AX16 - Eflornithine |
Probably not porphyrinogenic |
PNP |
Mono.Rationale
Eflornithine is administered topically and hepatic exposure is insignificant. Eflornithine is excreted in urine as unchanged drug and no metabolism is recognized.
Mono.ChemicalDescription
Ornithine decarboxylase inhibitor, alpha-difluoromethylornitine
Mono.TherapeuticCharacteristics
Eflornithine is used in the treatment of facial hirsutism in women. It is applied topically.
Mono.HepaticExposure
Cmax of efornithine is approximately 10 ng/mL (Malhotra 2001). This is equivalent to 0.05 µM and hepatic exposure is insignificant.
Mono.MetabolismAndPharmacokinetics
Eflornithine is not known to be metabolized and is eliminated in the urine as unchanged drug (SPC).
Less than 1 % of the drug is absorbed following topical application (Martindale).
Mono.SimilarDrugs
Mono.References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair.
Malhotra B, Noveck Rm, et al. J Clin Pharmacol. 2001 Sep;41(9):972-8.
|
11549102 |
| Drug reference publications | ||
| 2. | Martindale in Micromedex® 2.0 (electronic version). Eflornithine. (12.05.2015).
|
|
| Summary of Product Characteristics | ||
| 3. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Vaniqa).
|
|
Mono.Tradenames
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa 
Vaniqa